This article was originally published in The Gray Sheet
Executive SummaryPhilip Laughlin, president and chief operating officer, takes on the title of CEO Jan. 1, following the retirement of Herbert Stein as CEO and chairman. Stein will continue to serve as chairman emeritus while board member Albert Erani will become chairman
You may also be interested in...
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.